Sep 13,2023

Lunit's AI-Powered Mammography Analysis Solution Achieves Comparable Diagnostic Performance with Human Readers

Lunit has unveiled the results of a collaborative study with Dr. Yan Chen, Ph.D., professor of digital screening at the University of Nottingham, United Kingdom. The study, recently published in Radiology, demonstrates that Lunit's AI-powered mammography analysis solution, Lunit INSIGHT MMG, matches the diagnostic performance of human readers. The study, which involved comparing Lunit's solution with assessments by 552 human readers, represents a significant milestone in the field of medical imaging and the future of breast cancer detection.  Conducted retrospectively, the study evaluated two PERFORMS test sets, each consisting of 60 challenging cases from the NHSBSP (National Health Service Breast Screening Program), over a three-year period. Human readers assessed these cases between May 2018 and March 2021, while Lunit's AI-powered mammography analysis solution evaluated them in 2022.  In the study, no significant difference was observed in the AUC (area under the ROC curve) between Lunit's AI-powered mammography analysis solution (0.93) and human readers (0.88), demonstrating the solution's ability to excel in breast cancer detection.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 11,2023

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is spearheading a transformative change in breast cancer screening, bolstered by groundbreaking findings from a prospective study led by Dr. Fredrik Strand at the Karolinska Institutet, Sweden, involving over 50,000 women. Utilizing Lunit INSIGHT MMG, an FDA-cleared and CE-marked AI solution for mammography analysis, this research backs AI's potential to replace one human reader under Europe's double reading guideline and underscores its capacity to alleviate the strain on radiologists. Lunit INSIGHT MMG, collaborating with a single radiologist, exhibited a superior Cancer Detection Rate (CDR) of 4.7 per 1000, surpassing the traditional two-radiologist approach with a CDR of 4.5 per 1000. The study also showed a significant decline in recall rates (RR) with AI, both in collaboration with one radiologist (RR 2.8, 4.44% decrease) and when operating independently (RR 1.55, 47.1% decrease), compared to the double reading system (RR 2.93).

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 10,2023 TOP STORY

Mayo Clinic's AI Innovation Inspires Hope in Early Detection of Pancreatic Cancer

In a recent breakthrough, Mayo Clinic Comprehensive Cancer Center researchers used the world's most extensive imaging dataset to build a versatile artificial intelligence (AI) model that has shown the potential for autonomous detection of pancreatic cancer on standard CTs when surgical intervention can still promise a cure. The group developed a highly accurate AI model, trained on the largest - more than 3,000 patients - and most diverse CT dataset, for fully automated cancer detection, including small and otherwise difficult-to-detect tumors. Published in Gastroenterology, the journal of the American Gastroenterological Association, the study not only builds on the group's recent work on radiomics-based early detection models but also underscores Mayo Clinic's standing as a beacon of innovation in AI healthcare solutions.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 12,2023

mylife Loop improves health of pregnant women with type 1 diabetes and their babies

Women with type 1 diabetes have difficulties achieving the tight glycemic targets required due to their hormonal shifts and changed eating habits during pregnancy. Managing type 1 diabetes currently can result in hypoglycemia, weight gain and high blood pressure in the mother. In the AiDAPT clinical study, women used the CamAPS FX Hybrid Closed Loop technology for more than 95 per cent of the time. Compared to traditional insulin therapy methods, women who used the technology spent more time in the target range for pregnancy glucose levels (3.5 – 7.8 mmol/l) – 68 per cent vs 56 per cent, which is equivalent to an additional two-and-a-half to three hours every day throughout pregnancy, with no increased risk of hypoglycemia. The research team also found that women who used the technology gained 3.5 kg less weight and were less likely to have blood pressure complications during pregnancy.

CLINICAL STUDY

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Oct 12,2023

Glucotrack Announces Preclinical Testing With Implantable Continuous Glucose Monitor

Glucotrack, a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another milestone in its development of an implantable continuous glucose monitor (CGM) by commencing preclinical animal testing. The Company previously announced the completion and positive results of a laboratory-based feasibility study demonstrating that the CGM sensor design is capable of measuring glucose for at least two years post-implant. The objectives of the preclinical animal study were to assess the implant procedure techniques and tools as well as to determine the acute and chronic biological effect of the implant and the implant procedure.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 20,2021

Successful implementation of an ePRO remote monitoring system in patients receiving chemotherapy in a community oncology practice

Remote symptom monitoring of patients receiving cancer treatment has been shown to improve patient outcomes in the research setting. However, there is little evidence that this technology can be implemented and scaled in the real world with the same benefits. Beginning in June 2020, Highlands Oncology Group (HOG) offered patients receiving parenteral cancer therapy enrollment onto Expain: an EMR-integrated, electronic patient-reported outcomes (ePRO) system which enables remote symptom monitoring during systemic cancer therapy. From June 2020 – January 2021, HOG treated 1261 patients with IV chemotherapy. 769 patients were offered enrollment and 569 (73.9%) were successfully enrolled onto the ePRO system. REsults show that ePRO-based remote monitoring of patients receiving parenteral cancer therapy in routine clinical care is feasible. Patient enrollment and retention are high across all tumor types. Symptoms reported by patients were concordant with previous publications, and a small percent (7% of reports) required an acute office visit.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023 TOP STORY

New Robot could Help Diagnose Breast Cancer Early

The manipulator, designed by a team at the University of Bristol and based at the Bristol Robotics Laboratory, is able to apply very specific forces over a range similar to forces used by human examiners and can detect lumps using sensor technology at larger depths than before. The ultimate goal is that the device and sensors will have the capability to detect lumps more accurately and deeper than it is possible only from applying human touch. It could also be combined with other existing techniques, such as ultrasound examination.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 05,2023 TOP STORY

Computer Model Predicts Who Needs Lung Cancer Screening

A machine learning model equipped with only data on people's age, smoking duration and the number of cigarettes smoked per day can predict lung cancer risk and identify who needs lung cancer screening, according to a new study publishing October 3rd in the open access journal PLOS Medicine by Thomas Callender of University College London, UK, and colleagues. In the new study, researchers used data on 216,714 ever-smokers from the UK Biobank cohort and 26,616 ever-smokers participating in the US National Lung Screening trial to develop new models of lung cancer risk. The researchers tested the new model on a third set of data, from the US Prostate, Lung, Colorectal and Ovarian Screening Trial. The model predicted lung cancer incidence with an 83.9% sensitivity and lung cancer deaths with an 85.5% sensitivity.

CLINICAL STUDY

#ml

View Analyst & Ambassador Comments
Go to original news
Oct 09,2023 TOP STORY

New Research Demonstrates Clinical Effectiveness of Digital Treatment at Improving Insomnia and Comorbid Mental and Physical Health Issues

Big Health announced today the publication of two, peer-reviewed studies demonstrating the effects of its flagship digital insomnia treatment Sleepio in individuals with co-morbid insomnia and clinically significant anxiety as well as in stroke survivors. Published in the peer-reviewed Journal of Affective Disorders, researchers found that Sleepio’s clinically validated impact on insomnia also significantly reduced participants’ anxiety symptoms — 84% of improvements in anxiety were due to improvements in sleep. Also, the peer-reviewed Journal of Sleep Research published results from the INSPIRES study, a randomized controlled trial (RCT) comprising 84 stroke survivors demonstrating that Sleepio was effective at improving sleep, compared with sleep hygiene control, for at least eight weeks post-intervention. Results also showed that, among participants who had insomnia disorder at baseline, 71% in the Sleepio study arm achieved remission post-intervention compared to 30% of control participants.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 11,2023 TOP STORY

Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes

Better Therapeutics announced new findings from a recent subgroup analysis of AspyreRx (formerly BT-001) in its pivotal trial for type 2 diabetes (T2D). The analysis reveals that adjunctive use of AspyreRx with standard of care, including GLP-1 receptor agonists (GLP-1), leads to a substantially greater clinical improvement compared to control participants who did not incorporate AspyreRx into their regimen. The subgroup analysis, involving approximately 160 participants on GLP-1s randomized to the active and control arm of the study, exhibited an average reduction in HbA1c of 0.7% at 90 days, between the two groups. This exceeds the results of the entire BT-001 pivotal trial population, where AspyreRx outperformed the standard of care control arm by 0.4%. The new subgroup analysis data may be particularly relevant in the context of recent draft guidance from the FDA, titled 'Regulatory Considerations for Prescription Drug Use-Related Software,' released in September, which provides clarity about the agency’s views and intent to consider the combined effectiveness of pharmaceuticals and digital therapeutic solutions when making drug labeling decisions.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY